Immunome (NASDAQ:IMNM) (NASDAQ:IMNM) is a clinical‐stage biopharmaceutical company that specializes in the discovery and development of fully human therapeutic antibodies derived from naturally occurring immune repertoires. Utilizing its proprietary immune repertoire mining platform, the company captures and analyzes the diversity of antibodies produced by individuals who have successfully fought off disease, allowing it to identify potent, high-affinity candidates for a range of therapeutic indications. Based in Pittsburgh, Pennsylvania, Immunome’s technology is designed to accelerate antibody discovery while ensuring favorable safety and efficacy profiles.
The company’s pipeline spans oncology, infectious disease, and autoimmune disorders. By mining immunological memory, Immunome generates novel lead antibodies that can be advanced rapidly into preclinical and clinical development. Key therapeutic areas include B‐cell malignancies and emerging viral threats, with several programs currently in preclinical stages and at least one candidate approaching early‐phase clinical trials. In addition to internal development, Immunome partners with larger pharmaceutical firms and academic institutions to leverage its platform for antibody discovery across multiple disease targets.
Founded in 2016 as an offshoot of pioneering immunology research at the University of Pittsburgh, Immunome has grown under leadership with deep experience in drug development and translational science. The executive team is led by CEO David Humphreys, whose background includes senior roles in oncology research and biotech operations. The company’s scientific advisory board features leading immunologists and clinicians who guide target selection and strategic collaboration efforts.
While headquartered in the United States, Immunome maintains a global outlook, engaging in research collaborations and licensing discussions with partners in Europe and Asia. Its discovery platform can be applied across diverse therapeutic areas, positioning the company to address unmet medical needs worldwide. As Immunome advances its antibody candidates through the clinic, it aims to establish itself as a leader in next‐generation biologics derived from the human immune system.
